Serveur d'exploration SRAS

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Expanding the frontiers of existing antiviral drugs : Possible effects of HIV-1 protease inhibitors against SARS and avian influenza

Identifieur interne : 000652 ( PascalFrancis/Checkpoint ); précédent : 000651; suivant : 000653

Expanding the frontiers of existing antiviral drugs : Possible effects of HIV-1 protease inhibitors against SARS and avian influenza

Auteurs : Andrea Savarino [Italie]

Source :

RBID : Pascal:05-0475002

Descripteurs français

English descriptors

Abstract

When unexpected diseases such as the severe acute respiratory syndrome (SARS) and avian influenza become a serious threat to public health, an immediate response is imperative. This should take into consideration existing licensed antiviral drugs against other viral diseases already known to be safe for use in humans. In this report, evidence is presented that HIV-1 protease inhibitors (Pis) currently used in anti-HIV-1 therapies might exert some effects on SARS and perhaps, on avian influenza. Evidence for the potential benefits of PIs against the SARS coronavirus (SARS-CoV) is provided by empirical clinical studies, in vivo viral inhibition assays and computational simulations of the docking of these compounds to the active site of the main SARS-CoV protease. As suggested by in silico docking of these molecules to a theoretical model of a subunit of type A influenza virus RNA-dependent RNA polymerase, there also exists a remote possibility that these PIs may have an effect on avian influenza viruses. Although this evidence is still far from being definitive, the results so far obtained suggest that PIs should be seriously taken into consideration for further testing as potential therapeutic agents for SARS and avian influenza.


Affiliations:


Links toward previous steps (curation, corpus...)


Links to Exploration step

Pascal:05-0475002

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en" level="a">Expanding the frontiers of existing antiviral drugs : Possible effects of HIV-1 protease inhibitors against SARS and avian influenza</title>
<author>
<name sortKey="Savarino, Andrea" sort="Savarino, Andrea" uniqKey="Savarino A" first="Andrea" last="Savarino">Andrea Savarino</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Laboratory of Viral Immunology, Department of Infectious Diseases, Università Cattolica del Sacro Cuore, Largo Agostino Gemelli 8</s1>
<s2>00168 Rome</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<placeName>
<settlement type="city">Rome</settlement>
<region nuts="2">Latium</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">INIST</idno>
<idno type="inist">05-0475002</idno>
<date when="2005">2005</date>
<idno type="stanalyst">PASCAL 05-0475002 INIST</idno>
<idno type="RBID">Pascal:05-0475002</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000585</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000405</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000652</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000652</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a">Expanding the frontiers of existing antiviral drugs : Possible effects of HIV-1 protease inhibitors against SARS and avian influenza</title>
<author>
<name sortKey="Savarino, Andrea" sort="Savarino, Andrea" uniqKey="Savarino A" first="Andrea" last="Savarino">Andrea Savarino</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Laboratory of Viral Immunology, Department of Infectious Diseases, Università Cattolica del Sacro Cuore, Largo Agostino Gemelli 8</s1>
<s2>00168 Rome</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<placeName>
<settlement type="city">Rome</settlement>
<region nuts="2">Latium</region>
</placeName>
</affiliation>
</author>
</analytic>
<series>
<title level="j" type="main">Journal of clinical virology</title>
<title level="j" type="abbreviated">J. clin. virol.</title>
<idno type="ISSN">1386-6532</idno>
<imprint>
<date when="2005">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<title level="j" type="main">Journal of clinical virology</title>
<title level="j" type="abbreviated">J. clin. virol.</title>
<idno type="ISSN">1386-6532</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Antiretroviral agent</term>
<term>Antiviral</term>
<term>Avian influenza</term>
<term>Coronavirus</term>
<term>HIV-1 virus</term>
<term>Influenza A</term>
<term>Microbiology</term>
<term>Peptidases</term>
<term>RNA-directed RNA polymerase</term>
<term>Severe acute respiratory syndrome</term>
<term>Virology</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr">
<term>Virus HIV1</term>
<term>Coronavirus</term>
<term>Antiviral</term>
<term>Peptidases</term>
<term>Antirétroviral</term>
<term>RNA-directed RNA polymerase</term>
<term>Microbiologie</term>
<term>Virologie</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Grippe A</term>
<term>Grippe aviaire</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">When unexpected diseases such as the severe acute respiratory syndrome (SARS) and avian influenza become a serious threat to public health, an immediate response is imperative. This should take into consideration existing licensed antiviral drugs against other viral diseases already known to be safe for use in humans. In this report, evidence is presented that HIV-1 protease inhibitors (Pis) currently used in anti-HIV-1 therapies might exert some effects on SARS and perhaps, on avian influenza. Evidence for the potential benefits of PIs against the SARS coronavirus (SARS-CoV) is provided by empirical clinical studies, in vivo viral inhibition assays and computational simulations of the docking of these compounds to the active site of the main SARS-CoV protease. As suggested by in silico docking of these molecules to a theoretical model of a subunit of type A influenza virus RNA-dependent RNA polymerase, there also exists a remote possibility that these PIs may have an effect on avian influenza viruses. Although this evidence is still far from being definitive, the results so far obtained suggest that PIs should be seriously taken into consideration for further testing as potential therapeutic agents for SARS and avian influenza.</div>
</front>
</TEI>
<inist>
<standard h6="B">
<pA>
<fA01 i1="01" i2="1">
<s0>1386-6532</s0>
</fA01>
<fA03 i2="1">
<s0>J. clin. virol.</s0>
</fA03>
<fA05>
<s2>34</s2>
</fA05>
<fA06>
<s2>3</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG">
<s1>Expanding the frontiers of existing antiviral drugs : Possible effects of HIV-1 protease inhibitors against SARS and avian influenza</s1>
</fA08>
<fA11 i1="01" i2="1">
<s1>SAVARINO (Andrea)</s1>
</fA11>
<fA14 i1="01">
<s1>Laboratory of Viral Immunology, Department of Infectious Diseases, Università Cattolica del Sacro Cuore, Largo Agostino Gemelli 8</s1>
<s2>00168 Rome</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA20>
<s1>170-178</s1>
</fA20>
<fA21>
<s1>2005</s1>
</fA21>
<fA23 i1="01">
<s0>ENG</s0>
</fA23>
<fA43 i1="01">
<s1>INIST</s1>
<s2>26272</s2>
<s5>354000132618630020</s5>
</fA43>
<fA44>
<s0>0000</s0>
<s1>© 2005 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45>
<s0>33 ref.</s0>
</fA45>
<fA47 i1="01" i2="1">
<s0>05-0475002</s0>
</fA47>
<fA60>
<s1>P</s1>
</fA60>
<fA61>
<s0>A</s0>
</fA61>
<fA64 i1="01" i2="1">
<s0>Journal of clinical virology</s0>
</fA64>
<fA66 i1="01">
<s0>NLD</s0>
</fA66>
<fC01 i1="01" l="ENG">
<s0>When unexpected diseases such as the severe acute respiratory syndrome (SARS) and avian influenza become a serious threat to public health, an immediate response is imperative. This should take into consideration existing licensed antiviral drugs against other viral diseases already known to be safe for use in humans. In this report, evidence is presented that HIV-1 protease inhibitors (Pis) currently used in anti-HIV-1 therapies might exert some effects on SARS and perhaps, on avian influenza. Evidence for the potential benefits of PIs against the SARS coronavirus (SARS-CoV) is provided by empirical clinical studies, in vivo viral inhibition assays and computational simulations of the docking of these compounds to the active site of the main SARS-CoV protease. As suggested by in silico docking of these molecules to a theoretical model of a subunit of type A influenza virus RNA-dependent RNA polymerase, there also exists a remote possibility that these PIs may have an effect on avian influenza viruses. Although this evidence is still far from being definitive, the results so far obtained suggest that PIs should be seriously taken into consideration for further testing as potential therapeutic agents for SARS and avian influenza.</s0>
</fC01>
<fC02 i1="01" i2="X">
<s0>002A05C10</s0>
</fC02>
<fC02 i1="02" i2="X">
<s0>002B05C02J</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE">
<s0>Virus HIV1</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG">
<s0>HIV-1 virus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA">
<s0>HIV-1 virus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE">
<s0>Coronavirus</s0>
<s2>NW</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG">
<s0>Coronavirus</s0>
<s2>NW</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA">
<s0>Coronavirus</s0>
<s2>NW</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE">
<s0>Antiviral</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG">
<s0>Antiviral</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA">
<s0>Antiviral</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE">
<s0>Peptidases</s0>
<s2>FE</s2>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG">
<s0>Peptidases</s0>
<s2>FE</s2>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA">
<s0>Peptidases</s0>
<s2>FE</s2>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE">
<s0>Antirétroviral</s0>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG">
<s0>Antiretroviral agent</s0>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA">
<s0>Antiretroviral</s0>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE">
<s0>RNA-directed RNA polymerase</s0>
<s2>FE</s2>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG">
<s0>RNA-directed RNA polymerase</s0>
<s2>FE</s2>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA">
<s0>RNA-directed RNA polymerase</s0>
<s2>FE</s2>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE">
<s0>Microbiologie</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG">
<s0>Microbiology</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA">
<s0>Microbiología</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE">
<s0>Virologie</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG">
<s0>Virology</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA">
<s0>Virología</s0>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE">
<s0>Syndrome respiratoire aigu sévère</s0>
<s2>NM</s2>
<s5>14</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG">
<s0>Severe acute respiratory syndrome</s0>
<s2>NM</s2>
<s5>14</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA">
<s0>Síndrome respiratorio agudo severo</s0>
<s2>NM</s2>
<s5>14</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE">
<s0>Grippe A</s0>
<s5>15</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG">
<s0>Influenza A</s0>
<s5>15</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA">
<s0>Gripe A</s0>
<s5>15</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE">
<s0>Grippe aviaire</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG">
<s0>Avian influenza</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA">
<s0>Gripe aviar</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE">
<s0>Virus immunodéficience humaine</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG">
<s0>Human immunodeficiency virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA">
<s0>Human immunodeficiency virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE">
<s0>Lentivirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG">
<s0>Lentivirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA">
<s0>Lentivirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE">
<s0>Retroviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG">
<s0>Retroviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA">
<s0>Retroviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE">
<s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG">
<s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA">
<s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE">
<s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="ENG">
<s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="SPA">
<s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="06" i2="X" l="FRE">
<s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="06" i2="X" l="ENG">
<s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="06" i2="X" l="SPA">
<s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="07" i2="X" l="FRE">
<s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="07" i2="X" l="ENG">
<s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="07" i2="X" l="SPA">
<s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="08" i2="X" l="FRE">
<s0>Enzyme</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="08" i2="X" l="ENG">
<s0>Enzyme</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="08" i2="X" l="SPA">
<s0>Enzima</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="09" i2="X" l="FRE">
<s0>Nucleotidyltransferases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="09" i2="X" l="ENG">
<s0>Nucleotidyltransferases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="09" i2="X" l="SPA">
<s0>Nucleotidyltransferases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="10" i2="X" l="FRE">
<s0>Transferases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="10" i2="X" l="ENG">
<s0>Transferases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="10" i2="X" l="SPA">
<s0>Transferases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="11" i2="X" l="FRE">
<s0>Appareil respiratoire pathologie</s0>
<s5>13</s5>
</fC07>
<fC07 i1="11" i2="X" l="ENG">
<s0>Respiratory disease</s0>
<s5>13</s5>
</fC07>
<fC07 i1="11" i2="X" l="SPA">
<s0>Aparato respiratorio patología</s0>
<s5>13</s5>
</fC07>
<fC07 i1="12" i2="X" l="FRE">
<s0>Virose</s0>
</fC07>
<fC07 i1="12" i2="X" l="ENG">
<s0>Viral disease</s0>
</fC07>
<fC07 i1="12" i2="X" l="SPA">
<s0>Virosis</s0>
</fC07>
<fC07 i1="13" i2="X" l="FRE">
<s0>Infection</s0>
</fC07>
<fC07 i1="13" i2="X" l="ENG">
<s0>Infection</s0>
</fC07>
<fC07 i1="13" i2="X" l="SPA">
<s0>Infección</s0>
</fC07>
<fC07 i1="14" i2="X" l="FRE">
<s0>Poumon pathologie</s0>
<s5>16</s5>
</fC07>
<fC07 i1="14" i2="X" l="ENG">
<s0>Lung disease</s0>
<s5>16</s5>
</fC07>
<fC07 i1="14" i2="X" l="SPA">
<s0>Pulmón patología</s0>
<s5>16</s5>
</fC07>
<fN21>
<s1>332</s1>
</fN21>
<fN44 i1="01">
<s1>OTO</s1>
</fN44>
<fN82>
<s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
<affiliations>
<list>
<country>
<li>Italie</li>
</country>
<region>
<li>Latium</li>
</region>
<settlement>
<li>Rome</li>
</settlement>
</list>
<tree>
<country name="Italie">
<region name="Latium">
<name sortKey="Savarino, Andrea" sort="Savarino, Andrea" uniqKey="Savarino A" first="Andrea" last="Savarino">Andrea Savarino</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000652 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 000652 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PascalFrancis
   |étape=   Checkpoint
   |type=    RBID
   |clé=     Pascal:05-0475002
   |texte=   Expanding the frontiers of existing antiviral drugs : Possible effects of HIV-1 protease inhibitors against SARS and avian influenza
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021